文献速递食管与纵隔外科

食管癌术后使用酮咯酸与出血及急性肾损伤的关系

Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac.
PubMed 文献 · Ann Thorac Surg · 2020-09-24

本研究回顾性分析了2006至2018年单中心1019例食管腺癌食管切除术患者,其中67%术后使用酮咯酸。结论认为酮咯酸不增加术后急性肾损伤或出血风险。

要点

  • 食管癌术后酮咯酸使用率从2006年49%升至2018年92%。

核心结论

  • 食管切除术后使用酮咯酸不增加急性肾损伤或出血风险。

研究设计与样本

  • 单中心回顾性队列研究,纳入2006至2018年因食管腺癌行食管切除术的患者1019例。

主要发现

  • 1019例患者中123例(12%)发生术后事件(需输血和/或急性肾损伤)。
  • 686例(67%)术后使用酮咯酸,使用率从2006年49%(36/72)升至2018年92%(76/83)。
  • 仅接受三联治疗患者的亚组分析结果相似。

临床怎么用

  • 食管切除术后多模式镇痛可考虑使用酮咯酸,不增加出血或肾损伤风险。

局限性

  • 单中心回顾性研究,结果需外推验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As strategies promoting enhanced recovery protocols and opioid minimization techniques are increasingly prioritized, use of nonsteroidal antiinflammatory drugs continues to rise. Whether this prevalent use poses increased risk for bleeding or renal dysfunction in surgical populations after extensive dissection and fluid shifts is unclear. METHODS: We reviewed records of patients undergoing esophagectomy for a diagnosis of esophageal adenocarcinoma at a single institution from 2006 to 2018 for ketorolac administration during the postoperative hospital admission, as well as the occurrence of postoperative events, defined as the need for blood product transfusion and/or acute kidney injury. RESULTS: We identified 1019 patients, 123 of whom experienced postoperative events (12%). Ketorolac was administered to 686 (67%). Furthermore, ketorolac use steadily increased over the study period; 36 of 72 patients received this medication in 2006 (49%), and 76 of 83 in 2018 (92%). Multivariable logistic regression failed to identify a relationship between ketorolac administration (assessed as a binary covariate) and postoperative events (P = .657). Additional examination for a dose-response relationship using the cumulative total dose from the time of surgery to discharge also did not demonstrate a relationship with postoperative events (P = .829). In an effort to evaluate a more homogeneous population, we performed a subgroup analysis using only patients treated with trimodality therapy, which showed similar findings. CONCLUSIONS: Ketorolac has become a staple of multimodal postesophagectomy analgesic regimens. Importantly, this medication does not pose risk for acute kidney injury or bleeding after surgery.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Corsini EM, Zhou N, Antonoff MB, et al. Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. Ann Thorac Surg. 2020. PMID: 32980327. doi:10.1016/j.athoracsur.2020.07.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。